Virtual reality surgical training wins industry attention with scalable model

Tern plc

A virtual reality training platform developed by Fundamental XR and Orbis International has been awarded Gold in a major technology competition, highlighting how immersive tools are starting to gain traction in global medical education.

This programme, focused on ophthalmic surgery, allows medical trainees to practise procedures in a fully immersive virtual environment, without the limitations of physical equipment, live supervision or real-world patient risk. The result is a more accessible, standardised form of surgical education, especially valuable in countries where hospital training resources are limited or overstretched.

What sets this initiative apart is its focus on real-world application. The technology has been designed to fit the workflow and constraints of medical education systems in lower-resource settings. This combination of technical quality and real-world relevance is what earned the recognition, and it signals a step forward for VR in professional training markets.

Orbis brings decades of experience in eye care and surgical training around the world, while Fundamental XR provides the technical capability to deliver high-fidelity, scalable simulations. Together, they have built a tool that solves a pressing educational problem with modern technology, a clear use case with long-term potential.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search